Xenon Pharmaceuticals (NASDAQ:XENE) Releases Earnings Results, Beats Estimates By $0.05 EPS

Xenon Pharmaceuticals (NASDAQ:XENE) posted its earnings results on Thursday. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.05, FiscalAI reports. During the same quarter in the previous year, the firm earned ($1.07) EPS.

Here are the key takeaways from Xenon Pharmaceuticals’ conference call:

• Atera demand significantly exceeded expectations, with booked orders already well above the approximately 40 instruments the company expects to ship in 2026. Management said demand—not customer interest—is the constraint, with manufacturing capacity limiting near-term shipments.
• 10x raised its 2026 revenue outlook to $610 million–$630 million, implying 2%–5% underlying growth excluding settlement revenue. Second-quarter revenue was $151 million, or $149.4 million excluding the $1.6 million Takara settlement, while gross margin improved to 74%.
• Total instrument revenue fell 47% year over year, as customers delayed Xenium and Visium purchases ahead of Atera’s launch. Management expects a modest sequential revenue decline in Q3 from continued spatial transition effects before a significant Q4 increase as Atera shipments ramp.
• Core consumables remained resilient, with total consumables revenue up 7%, spatial consumables up 16%, and single-cell reaction volumes growing at a double-digit rate driven by Flex Apex. Management also characterized AI-driven demand for high-quality single-cell and spatial data as a significant long-term structural tailwind.
• Academic funding conditions remain tenuous; grant sentiment is improving, but funding has not yet translated consistently into purchasing because of allocation delays, oversight, and order-processing bottlenecks. The company’s guidance assumes the current macro environment persists rather than any meaningful academic-market recovery.

Xenon Pharmaceuticals Stock Performance

XENE stock traded down $1.19 during midday trading on Friday, reaching $63.36. 720,234 shares of the company traded hands, compared to its average volume of 1,308,280. The firm has a market capitalization of $6.13 billion, a price-to-earnings ratio of -13.48 and a beta of 0.62. Xenon Pharmaceuticals has a 52-week low of $32.78 and a 52-week high of $72.66. The business has a 50 day moving average of $60.06 and a 200-day moving average of $54.14.

Analysts Set New Price Targets

XENE has been the subject of several research reports. JPMorgan Chase & Co. increased their price objective on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a report on Wednesday, May 27th. Needham & Company LLC decreased their target price on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Royal Bank Of Canada dropped their price target on Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating for the company in a research note on Friday. Wall Street Zen upgraded Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and issued a $69.00 price objective on shares of Xenon Pharmaceuticals in a research note on Sunday, May 10th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $77.13.

Insider Buying and Selling

In other news, Director Gillian Cannon sold 1,190 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $63,236.60. Following the transaction, the director owned 1,455 shares of the company’s stock, valued at approximately $77,318.70. The trade was a 44.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Gary Patou sold 1,322 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the sale, the director owned 24,896 shares in the company, valued at $1,322,973.44. The trade was a 5.04% decrease in their position. The disclosure for this sale is available in the SEC filing. 2.91% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Several institutional investors have recently made changes to their positions in XENE. Danske Bank A S bought a new position in Xenon Pharmaceuticals during the 3rd quarter valued at about $32,000. Kestra Advisory Services LLC purchased a new position in shares of Xenon Pharmaceuticals during the fourth quarter valued at approximately $33,000. Osaic Holdings Inc. grew its stake in shares of Xenon Pharmaceuticals by 541.4% during the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 1,034 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Xenon Pharmaceuticals during the fourth quarter valued at approximately $43,000. Finally, State of Wyoming raised its holdings in shares of Xenon Pharmaceuticals by 30.4% in the fourth quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock worth $67,000 after buying an additional 350 shares during the period. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.